Friday, 20 Sep 2019

You are here

DRIVE Trial: Denosumab and Methotrexate Prevent Joint Erosions

Joint erosions in RA result from a complex process with multiple contributing mechanisms. One of those mechanisms involves RANK receptor activation by RANKL leading to osteoclast differentiation, activation and survival.

Denosumab is a fully human monoclonal antibody that binds specifically to human RANKL. Approved for treatment of osteoporosis, denosumab is now being investigated in RA studies, in view of its potential ability to inhibit the progression of bone erosion and bone loss.

The DRIVE study was a multicenter, randomized, double-blind, placebo-controlled, phase II study in Japan, conducted over 12 months. Japanese patients who had RA were randomized in a 1:1:1:1 ratio to receive one of four treatments: a placebo; denosumab 60 mg every 6 months (Q6M); denosumab 60 mg every 3 months (Q3M); or denosumab 60 mg every 2 months (Q2M). Radiographs at baseline, 6 and 12 months were submitted to the central analyzing center (Synarc, California, USA) for Modified Sharp score evaluation.

Denosumab significantly inhibited the progression of bone erosion at 12 months. The mean changes of the modified Sharp erosion score at 12 months from baseline were as follows:

  • 0.27 in denosumab Q6M
  • 0.14 in denosumab Q3M (p=0.0082)
  • 0.09 in denosumab Q2M (p=0.0036)
  • 0.99 in the placebo (p<0.0001).

Meanwhile, modified Sharp JSN (Joint Space Narrowing) score did not differ between denosumab and placebo groups.

Modified TSS was significantly different in all denosumab treatment groups as opposed to placebo at 12 months, but at 6 months only Q2M group appeared to show statistically significant difference. Investigators pointed out that effect of denosumab on BMD was not affected by steroid use in RA patients. Also, the safety profiles of denosumab groups were generally comparable with the placebo group.

The authors concluded that denosumab in combination with methotrexate has potential to be a new therapeutic option for patients with RA with risk factors for joint destruction.

The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Two vs. Four Weeks of Antibiotic Therapy in Septic Arthritis

A prospective trial has shown that 2 weeks of antibiotic therapy is as effective as 4 weeks of antibiotic therapy, with similar outcomes but shorter hospital stays.

This Swiss study was a prospective, unblinded, randomised, non-inferiority study comparing either 2 or 4 weeks of antibiotic therapy after surgical drainage of native joint bacterial arthritis in adults. 

Bimekizumab Add-on Therapy in Rheumatoid Arthritis

Bimekizumab is a dual inhibitor of IL-17A and IL-17F that has been shown to be effective in psoriasis and psoriatic arthritis. A proof-of-concept study shows that giving bimekizumab to rheumatoid arthritis patients not adequately controlled by certolizumab pegol resulted in a rapid decrease in disease activity achieved after 12 weeks of treatment. These findings are novel as anti-IL-17 monoclonal antibody therapy has previously been shown to be ineffective in RA.

74 Percent of Rheumatoid Arthritis Patients Dissatisfied with Treatment

CreakyJoints has completed a 258 patient survey showing that nearly three-fourths of people with rheumatoid arthritis (RA) have expressed dissatisfaction with their treatments, including conventional (csDMARDs) and biologic Disease Modifying Antirheumatic Drugs (bDMARDs).

RA Women are Less Likely to Breastfeed

A large pregnancy registry has published their results showing rheumatoid arthritis (RA) patients who become pregnant are less likely to breastfeed compared to non-RA women from the general population, with many women stopping breastfeeding so that they could start medication, even though many of these meds are safe to use during lactation.

Respiratory Risks Not Increased in RA Patients with COPD

An insurance claims based study of RA patients with COPD shows that biologics do not have an increased rate of respiratory events compared to those on conventional DMARDs. A real world cohort of RA patients with COPD was drawn from US-based MarketScan databases. Patients on biologic DMARDs and/or targeted synthetic DMARDs (tsDMARDs) were propensity matched to those on conventional synthetic DMARDs (csDMARDs).